Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 1% – Should You Sell?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s share price was down 1% on Monday . The company traded as low as $1.8503 and last traded at $1.91. 17,664 shares were traded during mid-day trading, an increase of 84% from the average daily volume of 9,605 shares. The stock had previously closed at $1.93.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Alaunos Therapeutics Price Performance

The firm has a market capitalization of $45.91 million, a P/E ratio of -0.98 and a beta of -1.00. The business has a 50 day moving average price of $2.06 and a 200 day moving average price of $2.55.

Alaunos Therapeutics (NASDAQ:TCRT) last announced its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Institutional Investors Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP bought a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics at the end of the most recent reporting period. Institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.